GAITHERSBURG, Md.--Oncormed here has received a US patent on a full-length coding sequence of the BRCA1 gene that encodes the entire BRCA1 protein. The company's rights in the patented sequence include therapeutics and diagnostic products and services. The company also recently received a worldwide exclusive license to the BRCA2 gene for diagnostic purposes.
"Our objective with respect to this intellectual property is to license BRCA1 for therapeutic use and to broadly license both BRCA1 and BRCA2 for diagnostic development and commercialization," noted Timothy Triche, Oncormed's chairman and CEO. Oncormed develops and provides gene-based diagnostic and information services.